New Zealand markets closed

ReShape Lifesciences Inc. (RSLS)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
0.2443-0.0106 (-4.16%)
At close: 04:00PM EDT
0.2374 -0.01 (-2.82%)
After hours: 07:58PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close0.2549
Open0.2340
Bid0.2412 x 600
Ask0.2446 x 1000
Day's range0.2201 - 0.2499
52-week range0.1410 - 2.5600
Volume2,121,895
Avg. volume5,247,995
Market cap5.731M
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ReShape Lifesciences® Reports First Quarter Ended March 31, 2024 Financial Results and Provides Corporate Update

    Commercial Launch of Next-Generation Lap-Band® 2.0 FLEX Continues Significant Reduction in Overall Operating Expenses of 51% in the First Quarter of 2024 Compared to the First Quarter of 2023 Implementation of 2024 Cost Reduction Plan Continues, Expected to Reduce Operating Expenses by 55.4% Compared to 2023 Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., May 15, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic

  • GlobeNewswire

    ReShape Lifesciences® to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate Update

    Conference Call to be Held at 4:30 pm ET on Wednesday, May 15, 2024IRVINE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the first quarter ended March 31, 2024, including a corporate update on Wednesday, May 15, 2024, after market.Management will host a conference call on May 15 at 4:30 pm ET. A live webcast will be avail

  • GlobeNewswire

    ReShape Lifesciences® Reports Year Ended December 31, 2023 Financial Results and Provides Corporate Update

    Completed First Surgeries With Next-Generation Lap-Band® 2.0 FLEX 2024 Operating Expenses Expected to Decrease by more than 50% Compared to 2023; Reaffirming Commitment to Profitability Conference Call to be Held at 4:30 pm ET Today IRVINE, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023